Literature DB >> 23399159

Scutellarin-cyclodextrin conjugates: synthesis, characterization and anticancer activity.

Bo Yang1, Yu-Lin Zhao, Xia Yang, Xia-Li Liao, Jian Yang, Ji-Hong Zhang, Chuan-Zhu Gao.   

Abstract

A series of scutellarin-cyclodextrin conjugates (SCU-CD conjugates), in which scutellarin was covalently bound to one of the primary hydroxyl groups of β-CD, were prepared, and their structures were determined using NMR and MS. These conjugates were further characterized by XRD and TG. The results showed that the aqueous solubility of the conjugates was much higher than that of scutellarin, and the conjugates could hardly be hydrolyzed to scutellarin in aqueous solutions. The cytotoxicity of SCU-CD conjugates on human colon cancer cell lines HT-29, SW480, Lovo and HTC116 indicated that the antitumor activities of the conjugates were better than that of scutellarin. This high antitumor activity, along with the satisfactory aqueous solubility and high stability of the conjugates, will be potentially useful for their application on human colon cancer chemotherapies. Crown
Copyright © 2012. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23399159     DOI: 10.1016/j.carbpol.2012.10.012

Source DB:  PubMed          Journal:  Carbohydr Polym        ISSN: 0144-8617            Impact factor:   9.381


  9 in total

Review 1.  Heterologous expression of 4α-glucanotransferase: overproduction and properties for industrial applications.

Authors:  Santhana Nakapong; Suthipapun Tumhom; Jarunee Kaulpiboon; Piamsook Pongsawasdi
Journal:  World J Microbiol Biotechnol       Date:  2022-01-07       Impact factor: 3.312

2.  Scutellarin suppresses human colorectal cancer metastasis and angiogenesis by targeting ephrinb2.

Authors:  Ping Ting Zhu; Ming Mao; Zhao Guo Liu; Li Tao; Bing Chun Yan
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

3.  Anti-Proliferative Effect of Rosmarinus officinalis L. Extract on Human Melanoma A375 Cells.

Authors:  Lucia Cattaneo; Rosella Cicconi; Giuseppina Mignogna; Alessandra Giorgi; Maurizio Mattei; Giulia Graziani; Rosalia Ferracane; Alessandro Grosso; Patrizia Aducci; M Eugenia Schininà; Mauro Marra
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

4.  Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy.

Authors:  Jingnan Wang; Jiayun Tan; Jiahao Luo; Peilin Huang; Wuyi Zhou; Luming Chen; Lingli Long; Li-Ming Zhang; Banghao Zhu; Liqun Yang; David Y B Deng
Journal:  J Nanobiotechnology       Date:  2017-03-01       Impact factor: 10.435

5.  Selective modifications at the different positions of cyclodextrins: a review of strategies.

Authors:  Jia Yue Liu; Xiao Zhang; Bing Ren Tian
Journal:  Turk J Chem       Date:  2020-04-01       Impact factor: 1.239

Review 6.  Emerging nanoformulation strategies for phytocompounds and applications from drug delivery to phototherapy to imaging.

Authors:  Hwa Seung Han; Song Yi Koo; Ki Young Choi
Journal:  Bioact Mater       Date:  2021-12-20

7.  Anti-colorectal cancer effects of scutellarin revealed by genomic and proteomic analysis.

Authors:  Liu-Lin Xiong; Ruo-Lan Du; Lu-Lu Xue; Ya Jiang; Jin Huang; Li Chen; Jia Liu; Ting-Hua Wang
Journal:  Chin Med       Date:  2020-03-26       Impact factor: 5.455

8.  Scutellarin Prevents Angiogenesis in Diabetic Retinopathy by Downregulating VEGF/ERK/FAK/Src Pathway Signaling.

Authors:  Lingli Long; Yubin Li; Shuang Yu; Xiang Li; Yue Hu; Tengfei Long; Liqin Wang; Wenwen Li; Xiaoxin Ye; Zunfu Ke; Haipeng Xiao
Journal:  J Diabetes Res       Date:  2019-12-28       Impact factor: 4.011

9.  Combined Scutellarin and C18H17NO6 Imperils the Survival of Glioma: Partly Associated With the Repression of PSEN1/PI3K-AKT Signaling Axis.

Authors:  Xiu-Ying He; Yang Xu; Qing-Jie Xia; Xiao-Ming Zhao; Shan Li; Xiao-Qiong He; Ru-Rong Wang; Ting-Hua Wang
Journal:  Front Oncol       Date:  2021-09-09       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.